Drug Trial Radar · NCT07550231
Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.
Conditions
- Osteoarthritis of the Knees
Interventions
AD-211-LDrug
Per oral, 1 tablet twice daily during the treatment period.
AD-211-MDrug
Per oral, 1 tablet twice daily during the treatment period.
AD-211-HDrug
Per oral, 1 tablet twice daily during the treatment period.
AD-2113Drug
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-211-L/MDrug
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-211-HDrug
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-2113Drug
Per oral, 1 tablet twice daily during the treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 100 mm Pain VAS score during activity over the past 24 hours in the target kneeTime frame: Baseline to Week13
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.